Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

TGF-beta1 has a dual role in carcinogenesis. In this gene, a leucine to proline substitution in codon 10 leads to higher circulating levels of TGF-beta1. This variant has been studied in relationship to the risk for breast cancer yielding contradicting results. We aim to unravel the relationship of this polymorphism and the risk of breast cancer. Women participating in the Rotterdam Study including 143 patients with incident breast cancer were genotyped for this polymorphism. We carried out a logistic regression and a survival analysis using age as the time variable. The logistic regression analysis showed an increased risk of breast cancer for Proline carriers (OR=1.4; 95% confidence interval (CI)=1.1-2.0) versus non-carriers. The survival analysis showed that carriers of the same allele had an increased risk of breast cancer (HR=1.4, 95% CI=1.1-2.0) against non-carriers. Our data suggest that the TGF-beta1 Leu10Pro polymorphism might play a role in breast cancer risk.

Original publication

DOI

10.1016/j.ejca.2006.08.021

Type

Journal article

Journal

European journal of cancer (Oxford, England : 1990)

Publication Date

01/2007

Volume

43

Pages

371 - 374

Addresses

Department of Epidemiology and Biostatistics, Erasmus University Medical Center, Postbus 1738, 3000 DR Rotterdam, The Netherlands.

Keywords

Humans, Breast Neoplasms, Disease-Free Survival, Regression Analysis, Gene Frequency, Genotype, Polymorphism, Genetic, Aged, Aged, 80 and over, Netherlands, Female, Transforming Growth Factor beta1